Results 111 to 120 of about 749,314 (382)

Biomimetic Co‐delivery of Lenvatinib and FePt Nanoparticles for Enhanced Ferroptosis/Apoptosis Treatment of Hepatocellular Carcinoma

Advanced Healthcare Materials, EarlyView.
This study introduces a novel HCC treatment using poly lactic‐co‐glycolic acid (PLGA) nanoparticles encased in HCC cell membranes to co‐deliver Lenvatinib and FePt nanoparticles. This approach improves treatment efficacy by enhancing ferroptosis and apoptosis.
Feichao Xuan, Xingyang Zhao, Weiran Pang, Zirong Li, Xiangyi Yin, Weizhong Xie, Xiaojun Zeng, Liming Nie, Junying Yang, Shiying Li, Puxiang Lai, Chihua Fang   +11 more
wiley   +1 more source

Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article

مجلة كلية الطب
Background: Acute myeloid leukemia is one of the deadliest hematologic malignancies that is marked by genetic alterations, abnormal cellular functions, and proliferation. Mutations in isocitrate dehydrogenase genes, particularly isocitrate dehydrogenase
Duha M. Bayram, Fadhel M. Lafta, Bassam F. Matti   +2 more
doaj   +1 more source

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Haematologica, 2019
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding
Vera Magistroni, Mario Mauri, Deborah D’Aliberti, Caterina Mezzatesta, Ilaria Crespiatico, Miriam Nava, Diletta Fontana, Nitesh Sharma, Wendy Parker, Andreas Schreiber, David Yeung, Alessandra Pirola, Sara Readelli, Luca Massimino, Paul Wang, Praveen Khandelwal, Stefania Citterio, Michela Viltadi, Silvia Bombelli, Roberta Rigolio, Roberto Perego, Jacqueline Boultwood, Alessandro Morotti, Giuseppe Saglio, Dong-Wook Kim, Susan Branford, Carlo Gambacorti-Passerini, Rocco Piazza   +27 more
doaj   +1 more source

Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy

Advanced Healthcare Materials, EarlyView.
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq, Punnya Anil Kumar Jeeja, Sudip Kumar Dam, Sabya Sachi Das, Juan L. Vivero‐Escoto   +4 more
wiley   +1 more source

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Journal of Medical Case Reports, 2011
Introduction In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions.
Scheid Christoph, Kochanek Matthias, Nogova Lucia, Rothe Achim, Shimabukuro-Vornhagen Alexander, von Bergwelt-Baildon Michael   +5 more
doaj   +1 more source

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2019
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States.
M. Tallman, E. Wang, J. Altman, F. Appelbaum, V. Bhatt, D. Bixby, S. Coutre, M. de Lima, A. Fathi, M. Fiorella, J. Foran, Aric Hall, Meagan A. Jacoby, J. Lancet, T. Leblanc, G. Mannis, G. Marcucci, Mike G Martin, A. Mims, M. O'donnell, R. Olin, D. Peker, A. Perl, D. Pollyea, K. Pratz, T. Prebet, F. Ravandi, P. Shami, R. Stone, S. Strickland, M. Wieduwilt, K. Gregory, Lydia Hammond, Ndiya Ogba   +33 more
semanticscholar   +1 more source

Chronic Myeloid Leukemia in 2020

HemaSphere, 2020
AbstractNew insights have emerged from maturing long‐term academic and commercial clinical trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of response has unexpectedly proved less important than hitherto thought, does not predict survival, and is of unclear relevance for treatment‐free remission (TFR).
openaire   +3 more sources

Inorganic Nanomaterials Meet the Immune System: An Intricate Balance

Advanced Healthcare Materials, EarlyView.
Metal nanomaterials influence the immune responses, such as cytokine production and T‐cell activity. Unintended immune modulation can have significant consequences while its fine‐tuning may transform the oncology care. Within this review, a critical analysis is offered regarding the nano/immune‐interaction and suggests the future research directions to
Gloria Pizzoli, Marco Gargaro, Giuliana Drava, Valerio Voliani   +3 more
wiley   +1 more source

Lipid metabolism in pancreatic cancer: emerging roles and potential targets

Cancer Communications, Volume 42, Issue 12, Page 1234-1256, December 2022., 2022
Abstract Pancreatic cancer is one of the most serious health issues in developed and developing countries, with a 5‐year overall survival rate currently <9%. Patients typically present with advanced disease due to vague symptoms or lack of screening for early cancer detection.
Xinpeng Yin, Ruiyuan Xu, Jianlu Song, Rexiati Ruze, Yuan Chen, Chengcheng Wang, Qiang Xu   +6 more
wiley   +1 more source

IRE1 alpha may be causing abnormal loss of p53 at post transcriptional level in chronic myeloid leukemia [PDF]

arXiv, 2017
Current treatment strategy for chronic myeloid leukemia (CML) mainly includes inhibition of tyrosine kinase activity, which has dramatically improved the prognosis of the disease but without cure. In addition some patients may become drug resistant. Thus there is still the need for other therapies to avoid resistance and if possible to cure the disease.
arxiv